Paragraphs
Precision Trial
 

The PRECISION Trial

This trial was designed to provide additional data on the Eversense CGM system across three metrics:

  • System accuracy within the first 30 days after Sensor insertion
  • Plasma dexamethasone concentration profiles after Sensor insertion
  • Additional safety and accuracy data for use up to 90 days

A total of 35 adults with Type 1 and Type 2 diabetes were inserted and evaluated. Glucose data was gathered in clinic at days 1, 7, 14, 30, 60 and 90. Results support the targeted indication, demonstrating the accuracy and safety of the Eversense CGM System for its intended use.

 
Selector Id
precision-trial
Selector Class
precision-trial
Precision Studies Result

Number of Subjects

Precise II

90

adults
(≥ 18 years)

Total number of paired CGM and YSI reference

15,753

Percent within 15/15%

87%

Percent within 20/20%

94%

Percent within 30/30%

99%

Percent within 40/40%

100%

MARD

8.5%

Number of Subjects

Precision

35

adults
(≥ 18 years)

Total number of paired CGM and YSI reference

15,170

Percent within 15/15%

85%

Percent within 20/20%

93%

Percent within 30/30%

98%

Percent within 40/40%

99%

MARD

9.6%

Selector Id
precision-studies-result
Selector Class
precision-studies-result
Download Publication
Selector Id
section-download
Selector Class
section-download
Sub Description

The advanced sensor technology and under-the-skin sensor help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.